Literature DB >> 24338934

Vitamin D status of human immunodeficiency virus-positive patients with advanced liver disease enrolled in the solid organ transplantation in HIV: multi-site study.

Andrea D Branch1, Burc Barin, Adeeb Rahman, Peter Stock, Thomas D Schiano.   

Abstract

An optimal vitamin D status may benefit liver transplantation (LT) patients. Higher levels of 25-hydroxyvitamin D [25(OH)D] mitigate steroid-induced bone loss after LT, correlate with better hepatitis C virus treatment responses, and increase graft survival. This study investigated 25(OH)D levels and assessed strategies for vitamin D deficiency prevention in human immunodeficiency virus (HIV)-positive patients with advanced liver disease who were enrolled in the Solid Organ Transplantation in HIV: Multi-Site Study. 25(OH)D was measured in banked specimens from 154 LT candidates/recipients with the DiaSorin assay; deficiency was defined as a 25(OH)D level < 20 ng/mL. Information about vitamin D supplement use after LT was obtained from medication logs and via surveys. Logistic regression, Cox regression, and linear repeated measures analyses were performed with SAS software. We found that none of the 17 academic medical centers in the United States routinely recommended vitamin D supplements before LT, and only a minority (4/17) recommended vitamin D supplements to all patients after LT. Seventy-one percent of the 139 patients with pre-LT values had vitamin D deficiency, which was significantly associated with cirrhosis (P = 0.01) but no other variable. The vitamin D status improved modestly after LT; however, the status was deficient for 40% of the patients 1 year after LT. In a multivariate linear repeated measures model, a higher pre-LT 25(OH)D level (P < 0.001), specimen collection in the summer (P < 0.001), a routine vitamin D supplementation strategy after LT (P < 0.001), and the time elapsing since LT (P = 0.01) were significantly associated with increases in the post-LT 25(OH)D level; black race was associated with a decreased level (P = 0.02). In conclusion, the majority of patients awaiting LT were vitamin D deficient, and approximately half were vitamin D deficient after LT. More extensive use of vitamin D supplements, more sun exposure, or both are needed to prevent this deficiency in HIV-positive LT candidates and recipients.
© 2013 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24338934      PMCID: PMC3946843          DOI: 10.1002/lt.23784

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  39 in total

1.  Is lower serum 25-hydroxy vitamin D associated with efavirenz or the non-nucleoside reverse transcriptase inhibitor class?

Authors:  Christoph A Fux; Sandra Baumann; Hansjakob Furrer; Nicolas J Mueller
Journal:  AIDS       Date:  2011-03-27       Impact factor: 4.177

2.  Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C.

Authors:  Edmondo Falleti; Davide Bitetto; Carlo Fabris; Giovanna Fattovich; Annarosa Cussigh; Sara Cmet; Elisa Ceriani; Ezio Fornasiere; Michela Pasino; Donatella Ieluzzi; Mario Pirisi; Pierluigi Toniutto
Journal:  Hepatology       Date:  2012-10-14       Impact factor: 17.425

Review 3.  Vitamin D for your patients with chronic hepatitis C?

Authors:  Adeeb H Rahman; Andrea D Branch
Journal:  J Hepatol       Date:  2012-08-04       Impact factor: 25.083

4.  Vitamin D and the racial difference in the genotype 1 chronic hepatitis C treatment response.

Authors:  Steven J Weintraub; Jacquelyn F Fleckenstein; Tony N Marion; Margaret A Madey; Tahar M Mahmoudi; Kenneth B Schechtman
Journal:  Am J Clin Nutr       Date:  2012-09-26       Impact factor: 7.045

5.  Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D Levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population.

Authors:  Christine N Dao; Pragna Patel; E Turner Overton; Frank Rhame; Sherri L Pals; Christopher Johnson; Timothy Bush; John T Brooks
Journal:  Clin Infect Dis       Date:  2011-02-01       Impact factor: 9.079

Review 6.  Vitamin D and bone.

Authors:  Daniel D Bikle
Journal:  Curr Osteoporos Rep       Date:  2012-06       Impact factor: 5.096

7.  The prevalence of hypovitaminosis D among US adults: data from the NHANES III.

Authors:  Ashraf Zadshir; Naureen Tareen; Deyu Pan; Keith Norris; David Martins
Journal:  Ethn Dis       Date:  2005       Impact factor: 1.847

8.  HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D.

Authors:  Mario Cozzolino; Marcos Vidal; Maria Vittoria Arcidiacono; Pablo Tebas; Kevin E Yarasheski; Adriana S Dusso
Journal:  AIDS       Date:  2003-03-07       Impact factor: 4.177

9.  High frequency of vitamin D deficiency in HIV-infected patients: effects of HIV-related factors and antiretroviral drugs.

Authors:  C Allavena; C Delpierre; L Cuzin; D Rey; N Viget; J Bernard; P Guillot; C Duvivier; E Billaud; F Raffi
Journal:  J Antimicrob Chemother       Date:  2012-05-15       Impact factor: 5.790

10.  Decrease of vitamin D concentration in patients with HIV infection on a non nucleoside reverse transcriptase inhibitor-containing regimen.

Authors:  Anali Conesa-Botella; Eric Florence; Lutgarde Lynen; Robert Colebunders; Joris Menten; Rodrigo Moreno-Reyes
Journal:  AIDS Res Ther       Date:  2010-11-23       Impact factor: 2.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.